Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis

AIM: Fuzhenghuayu (FZHY) capsule can inhibit the progression of cirrhosis. This study explored whether FZHY can reduce the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis B-caused cirrhosis (HBC) undergoing antiviral therapy. METHODS: A retrospective review of 842 patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Ke, Liu, Yao, Wang, Xiaojing, Li, Yuxin, Zhang, Qun, Hu, Ying, Ran, Chongping, Huang, Yunyi, Hou, Jie, Wang, Xianbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644307/
https://www.ncbi.nlm.nih.gov/pubmed/33178324
http://dx.doi.org/10.1155/2020/8826091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644307/
https://www.ncbi.nlm.nih.gov/pubmed/33178324
http://dx.doi.org/10.1155/2020/8826091

Ejemplares similares